"Tumor Stem Cell Assay" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
| Descriptor ID |
D014410
|
| MeSH Number(s) |
E01.370.225.500.383.910 E01.370.225.500.388.930 E05.200.500.383.910 E05.200.500.388.930 E05.242.383.910 E05.242.417.500 E05.337.550.200.800
|
| Concept/Terms |
Tumor Stem Cell Assay- Tumor Stem Cell Assay
- Colony Forming Units Assay, Tumor
- Neoplasm Stem Cell Assay
- Stem Cell Assay, Tumor
- Clonogenic Cell Assay, Tumor
- Colony-Forming Units Assay, Tumor
|
Below are MeSH descriptors whose meaning is more general than "Tumor Stem Cell Assay".
Below are MeSH descriptors whose meaning is more specific than "Tumor Stem Cell Assay".
This graph shows the total number of publications written about "Tumor Stem Cell Assay" by people in this website by year, and whether "Tumor Stem Cell Assay" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 4 | 4 |
| 1995 | 0 | 4 | 4 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 7 | 7 |
| 1998 | 0 | 2 | 2 |
| 1999 | 1 | 7 | 8 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 3 | 3 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 7 | 7 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 7 | 7 |
| 2008 | 0 | 7 | 7 |
| 2009 | 0 | 6 | 6 |
| 2010 | 0 | 4 | 4 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 5 | 6 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 5 | 5 |
| 2015 | 0 | 4 | 4 |
| 2016 | 0 | 4 | 4 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 4 | 4 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Stem Cell Assay" by people in Profiles.
-
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Rep Med. 2021 09 21; 2(9):100394.
-
GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Cells. 2021 04 06; 10(4).
-
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Nat Metab. 2020 12; 2(12):1401-1412.
-
Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. Nat Metab. 2020 08; 2(8):775-792.
-
Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis. Mol Oncol. 2020 08; 14(8):1760-1778.
-
WIP1 dephosphorylation of p27Kip1 Serine 140 destabilizes p27Kip1 and reverses anti-proliferative effects of ATM phosphorylation. Cell Cycle. 2020 02; 19(4):479-491.
-
Fasting Reduces Intestinal Radiotoxicity, Enabling Dose-Escalated Radiation Therapy for Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2019 11 01; 105(3):537-547.
-
IITZ-01, a novel potent lysosomotropic autophagy inhibitor, has single-agent antitumor efficacy in triple-negative breast cancer in vitro and in vivo. Oncogene. 2019 01; 38(4):581-595.
-
Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A. J Med Chem. 2018 04 12; 61(7):3193-3208.
-
The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells. J Neurooncol. 2018 May; 137(3):481-492.